Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Mendus Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Mendus şirketinin kazançları yıllık ortalama -13.3% oranında azalırken, Biotechs sektörünün kazançları yıllık 13.4% oranında artan oldu. Gelirler yıllık ortalama 26.7% oranında artan oldu.

Anahtar bilgiler

-13.3%

Kazanç büyüme oranı

21.4%

EPS büyüme oranı

Biotechs Sektör Büyümesi	0.7%
Gelir büyüme oranı	26.7%
Özkaynak getirisi	-20.2%
Net Marj	-447.6%
Sonraki Kazanç Güncellemesi	08 Nov 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Mendus AB (publ) (STO:IMMU) Shares Could Be 24% Above Their Intrinsic Value Estimate

Aug 31

Gelir ve Gider Dağılımı

Mendus nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

OM:IMMU Gelir, gider ve kazançlar (SEK Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	32	-141	37	112
31 Mar 24	28	-107	36	102
31 Dec 23	28	-102	37	93
30 Sep 23	2	-104	41	84
30 Jun 23	1	-116	49	89
31 Mar 23	1	-141	50	88
31 Dec 22	3	-139	49	87
30 Sep 22	2	-128	47	79
30 Jun 22	2	-117	41	72
31 Mar 22	2	-119	41	75
31 Dec 21	0	-133	43	86
30 Sep 21	0	-148	41	83
30 Jun 21	0	-138	34	80
31 Mar 21	0	-119	27	68
31 Dec 20	0	-89	18	48
30 Sep 20	16	3	2	7
30 Jun 20	16	-11	4	19
31 Mar 20	17	-31	9	35
31 Dec 19	17	-48	13	49
30 Sep 19	0	-118	26	91
30 Jun 19	0	-112	27	85
31 Mar 19	0	-98	26	72
31 Dec 18	0	-98	26	71
30 Sep 18	0	-90	25	66
30 Jun 18	0	-89	23	65
31 Mar 18	0	-88	22	66
31 Dec 17	0	-80	23	58
30 Sep 17	0	-86	41	45
30 Jun 17	0	-77	48	28
31 Mar 17	0	-72	58	14
31 Dec 16	0	-61	61	0
30 Sep 16	0	-48	47	0
30 Jun 16	0	-44	43	0
31 Mar 16	0	-37	37	0
31 Dec 15	0	-38	38	0
30 Sep 15	0	-37	38	0
30 Jun 15	0	-36	36	0
31 Mar 15	0	-33	34	0
31 Dec 14	0	-28	28	0
30 Sep 14	0	-21	22	0
30 Jun 14	0	-16	17	0
31 Mar 14	0	-13	14	0

Kaliteli Kazançlar: IMMU şu anda kârlı değil.

Büyüyen Kar Marjı: IMMU şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: IMMU kârlı değildir ve zararlar son 5 yılda yılda 13.3% oranında artmıştır.

Büyüme Hızlandırma: IMMU 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: IMMU kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( -18.6% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: IMMU hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -20.25% ) sahiptir.

Mendus Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Mendus AB (publ) to Report Q3, 2024 Results on Nov 08, 2024

Mendus AB (publ) to Report Fiscal Year 2022 Final Results on Apr 17, 2023

Mendus AB (publ) to Report Q1, 2023 Results on May 12, 2023

Immunicum AB (publ) to Report Fiscal Year 2021 Final Results on Apr 15, 2022

Immunicum AB (publ) to Report Q1, 2022 Results on May 10, 2022

Recent updates

New minor risk - Profitability

No longer forecast to breakeven

Now 20% overvalued

Mendus AB (publ) (STO:IMMU) Shares Could Be 24% Above Their Intrinsic Value Estimate

Now 24% overvalued

Mendus AB (Publ) Announces Board Changes

Mendus AB (Publ) Announces Board Changes

Independent Director exercised options to buy kr460k worth of stock.

Mendus AB (publ) Announces Ethics Committee Approval for the AMLM22-CADENCE Trial with Lead Product Vididencel in AML

Chief Executive Officer recently bought kr120k worth of stock

We're Keeping An Eye On Mendus' (STO:IMMU) Cash Burn Rate

Mendus AB (Publ) Announces Clinical Pipeline Update

Consensus revenue estimates increase by 172%

Mendus AB (Publ) Appoints Ted Fjällman as Board Member

Mendus AB Announces Positive Survival Data from Phase 2 Advance II Trial Evaluating Vididencel as Maintenance Therapy for AML at ASH 2023

Consensus revenue estimates decrease by 63%

Mendus AB (publ) to Report Q3, 2024 Results on Nov 08, 2024

Consensus revenue estimates increase by 172%

Mendus AB (publ), Annual General Meeting, May 17, 2024

New major risk - Share price stability

Mendus Announces Phase 1 vididencel Clinical Trial Results in AML and High-Risk MDS Patients Published in Peer-Reviewed Medical Journal

Mendus AB (Publ) Announces Multiple Abstracts to Be Presented At Ash 2023 Including Oral Presentation on Advance Ii Survival Data

Mendus AB to Present Novel Data Supporting the Broad Potential of its Proprietary Cancer Vaccine Platform at CICON23

Mendus AB Receives U.S. FDA Fast Track Designation forididencel in Acute Myeloid Leukemia

New minor risk - Profitability

Forecast breakeven date pushed back to 2025

New major risk - Shareholder dilution

Mendus AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 90 million.

New major risk - Market cap size

Mendus AB Appoints Lewis Lanier to Scientific Advisory Board

Mendus AB Presents Comprehensive Advance II Immunomonitoring Data at the EHA Annual Meeting 2023

Mendus AB (publ) announced that it expects to receive funding from Flerie Invest AB

No longer forecast to breakeven

Mendus (STO:IMMU) Is Making Moderate Use Of Debt

Price target decreased by 23% to kr5.00

Forecast breakeven date pushed back to 2024

Mendus AB (publ) to Report Fiscal Year 2022 Final Results on Apr 17, 2023

Mendus AB (publ) to Report Q1, 2023 Results on May 12, 2023

Mendus AB (publ) Presents Positive Survival Data from the Advance II Trial Evaluating DCP-001 as A Maintenance Therapy in AML At the American Society of Hematology Meeting

Is Mendus (STO:IMMU) Using Debt Sensibly?

Price target decreased to kr5.30

High number of new and inexperienced directors

Mendus AB Announces Nomination Committee for 2023 Annual General Meeting

Mendus to Report Positive Clinical and Preclinical Data in Ovarian Cancer At the European Society of Gynaecological Oncology 2022 Congress

Is Mendus (STO:IMMU) Using Debt Sensibly?

Mendus AB (Publ) Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition

Chief Financial Officer recently bought kr216k worth of stock

Immunicum AB (publ) Announces Positive Interim Results from ADVANCE II Study in AML Maintenance Treatment

Health Check: How Prudently Does Immunicum (STO:IMMU) Use Debt?

Immunicum AB Presents Preclinical Data Demonstrating Synergy of Dcp-001 with Standard Treatments for Acute Myeloid Leukemia

High number of new and inexperienced directors

Forecast to breakeven in 2023

Chief Financial Officer recently bought kr97k worth of stock

Immunicum AB (publ) to Report Fiscal Year 2021 Final Results on Apr 15, 2022

Immunicum AB (publ) to Report Q1, 2022 Results on May 10, 2022

Is Immunicum (STO:IMMU) Using Too Much Debt?

Chief Executive Officer recently bought kr252k worth of stock

Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021

Forecast to breakeven in 2023

Immunicum Announces Completion of Phase Ib Portion and Early Closure of ILIAD Study

Immunicum AB Publishes DCP-001 Mechanism of Action in the Journal Cells

Immunicum Announces Enrollment of First Patient in Phase I ALISON Study Evaluating Cancer Relapse Vaccine Candidate DCP-001 in Ovarian Cancer

Chief Executive Officer recently bought kr2.4m worth of stock

Interim Chairman of the Board recently bought kr183k worth of stock

Independent Director has left the company

Immunicum AB Presents Preclinical Data for Ilixadencel and DCP-001 At the 18Th Cancer Immunotherapy Annual Meeting

Immunicum AB (Publ) Announces Updated Executive Management Team After Business Combination

Chief Medical Officer has left the company

Immunicum AB Appoints Jeroen Rovers, M.D., Ph.D., to the Position of Chief Medical Officer

Executive Officer has left the company